Day One Biopharmaceuticals
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
Day One Biopharmaceuticals
May 1, 2024, 16:49 |
Blog
Samuel Blackman: As many of you know, I do like to write things
Samuel Blackman, Founder and Head of Research and Development at Day One Biopharmaceuticals, shared on…
Apr 28, 2024, 13:23 |
Drugs
Sam Blackman: US FDA approved the first targeted medicine for the treatment of patients with relapsed or refractory pediatric low-grade glioma
Sam Blackman, Co-founder and Chief Medical Officer of Day One Biopharmaceuticals, shared a post by Day…
Apr 24, 2024, 17:24 |
Blog
U.S. FDA approved the first targeted medicine for the treatment of patients with relapsed or refractory pediatric low-grade glioma - Day One Biopharmaceuticals
Day One Biopharmaceuticals shared a post on LinkedIn: "Breaking News: Today, we are thrilled to share…
Feb 26, 2024, 11:23 |
Insight
Samuel Blackman shares the Day One journey to reshape pediatric cancer drug development - Day One Biopharmaceuticals
Day One Biopharmaceuticals shared on their LinkedIn: "Head of R&D and co-founder Samuel Blackman shares…
All:
4
Posts:
1 - 10
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Barbara Jereczek-Fossa has been elected as the ESTRO President-elect!
Facebook
RSS Feed
Twitter
Linkedin
Youtube